Biogen Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chris Viehbacher

Algemeen directeur

US$4.1m

Totale compensatie

Percentage CEO-salaris	39.3%
Dienstverband CEO	2yrs
Eigendom CEO	0.005%
Management gemiddelde ambtstermijn	4.5yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Viehbacher's beloning veranderd ten opzichte van Biogen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$4m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$30m	US$154k	US$3b

Compensatie versus markt: De totale vergoeding ($USD 4.07M ) Chris } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de CL markt ($USD 5.75M ).

Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chris Viehbacher (63 yo)

2yrs

Tenure

US$4,069,913

Compensatie

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Viehbacher	President	2yrs	US$4.07m	0.0048% CLP 1.1b
Michael McDonnell	Executive VP & CFO	4.3yrs	US$7.17m	0.013% CLP 3.0b
Nicole Murphy	Head of Pharmaceutical Operations & Technology	2.8yrs	US$5.71m	0.0066% CLP 1.5b
Susan Alexander	Executive VP & Chief Legal Officer	18.8yrs	US$6.70m	0.035% CLP 8.0b
Rachid Izzar	Head of Global Product Strategy & Commercialization	3.8yrs	US$5.45m	0.0067% CLP 1.5b
Robin Kramer	Senior VP & Chief Accounting Officer	6yrs	geen gegevens	0.0043% CLP 968.8m
Stephen Amato	Head of Investor Relations	less than a year	geen gegevens	geen gegevens
Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	4.8yrs	geen gegevens	geen gegevens
Adam Keeney	Executive VP & Head of Corporate Development	1.6yrs	geen gegevens	0.00045% CLP 102.1m
Ginger Gregory	Executive VP & Chief Human Resources Officer	7.3yrs	US$5.08m	0.0093% CLP 2.1b
Alisha Alaimo	President & Head of North America	7.3yrs	geen gegevens	geen gegevens
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	7.3yrs	geen gegevens	geen gegevens

4.5yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BIIBCL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Viehbacher	President	2yrs	US$4.07m	0.0048% CLP 1.1b
Stephen Sherwin	Independent Director	14.7yrs	US$435.32k	0.013% CLP 2.9b
William Hawkins	Independent Director	5.4yrs	US$425.73k	0.0044% CLP 1.0b
Caroline Dorsa	Independent Chair of the Board	14.8yrs	US$646.13k	0.017% CLP 3.9b
Eric Rowinsky	Independent Director	14.7yrs	US$418.02k	0.014% CLP 3.2b
Maria Freire	Independent Director	3.4yrs	US$412.90k	0.0031% CLP 692.0m
Lloyd Minor	Directors	less than a year	geen gegevens	geen gegevens
Monish Patolawala	Independent Director	less than a year	geen gegevens	0.00092% CLP 208.7m
Jesus Mantas	Independent Director	5.4yrs	US$433.23k	0.0051% CLP 1.2b
Susan Langer	Independent Director	1.4yrs	US$334.53k	0.0019% CLP 428.8m

4.4yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIIBCL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Biogen Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

Biogen Inc., Annual General Meeting, Jun 20, 2024

Executive VP recently sold CL$19m worth of stock

Recent updates

Investor sentiment deteriorates as stock falls 42%

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Third quarter 2024 earnings released: EPS: US$2.67 (vs US$0.47 loss in 3Q 2023)

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

Second quarter 2024 earnings released: EPS: US$4.01 (vs US$4.09 in 2Q 2023)

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

New minor risk - Insider selling

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.69 in 1Q 2023)

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Executive VP recently sold CL$19m worth of stock

Insider recently sold CL$57m worth of stock

Independent Director recently bought CL$98m worth of stock

Full year 2023 earnings released: EPS: US$8.02 (vs US$20.97 in FY 2022)

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$7.86 profit in 3Q 2022)

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings released: EPS: US$4.09 (vs US$7.25 in 2Q 2022)

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Insider recently sold CL$645m worth of stock

First quarter 2023 earnings released: EPS: US$2.69 (vs US$2.07 in 1Q 2022)

Executive VP recently sold CL$21m worth of stock

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden